

The key elements of the BAF are:

- A description of each Principal (strategic) Risk, that forms the basis of the Trust's risk framework (with corresponding corporate and operational risks defined at a Trust-wide and service level)
- Risk ratings current (residual), tolerable and target levels
- Clear identification of primary strategic threats and opportunities that are considered likely to increase or reduce the Principal Risk, within which they are expected to materialise
- A statement of risk appetite for each threat and opportunity, to be defined by the Lead Committee on behalf of the Board (Averse = aim to avoid the risk entirely; Minimal = insistence on low risk options; Cautious = preference for low risk options; Open = prepared to accept a higher level of residual risk than usual, in pursuit of potential benefits)
- Key elements of the risk treatment strategy identified for each threat and opportunity, each assigned to an executive lead and individually rated by the lead committee for the level of assurance they can take that the strategy will be effective in treating the risk (see below for key)
- Sources of assurance incorporate the three lines of defence: (1) Management (those responsible for the area reported on); (2) Risk and compliance functions (internal but independent of the area reported on); and (3) Independent assurance (Internal audit and other external assurance providers)
- Clearly identified gaps in the primary control framework, with details of planned responses each assigned to a member of the Senior Leadership Team (SLT) with agreed timescales

Key to lead committee assurance ratings:

- Green = Positive assurance: the Committee is satisfied that there is reliable evidence of the appropriateness of the current risk treatment strategy in addressing the threat or opportunity
 - no gaps in assurance or control AND current exposure risk rating = target
 OR
 - gaps in control and assurance are being addressed
- Amber = Inconclusive assurance: the Committee is not satisfied that there is sufficient evidence to be able to make a judgement as to the appropriateness of the current risk treatment strategy
- Red = Negative assurance: the Committee is satisfied that there is sufficient reliable evidence that the current risk treatment strategy is not appropriate to the nature and/or scale of the threat or opportunity

This approach informs the agenda and regular management information received by the relevant lead committees, to enable them to make informed judgements as to the level of assurance that they can take and which can then be provided to the Board in relation to each Principal Risk and also to identify any further action required to improve the management of those risks.

		Likelihood so	ore and descripto	or	
	Very unlikely 1	Unlikely 2	Possible 3	Somewhat likely 4	Very likely 5
Frequency How often might/does it happen	This will probably never happen/recur	Do not expect it to happen/recur but it is possible it may do so	Might happen or recur occasionally or there are a significant number of near misses / incidents at a lower consequence level	Will probably happen/recur, but it is not a persisting issue/ circumstances	Will undoubtedly happen/recur, possibly frequently
Probability Will it happen or not?	Less than 1 chance in 1,000 (< 0.1%)	Between 1 chance in 1,000 and 1 in 100 (0.1 - 1%)	Between 1 chance in 100 and 1 in 10 (1- 10%)	Between 1 chance in 10 and 1 in 2 (10 - 50%)	Greater than 1 chance in 2 (>50%)

Board committees should review the BAF with particular reference to comparing the tolerable risk level to the current exposure risk rating

This BAF includes the following Principal Risks (PRs) to the Trust's strategic priorities:

Reference	Principal risk	Lead committee	Initial date of assessment	Last reviewed	Target risk score C x L	Previous risk score (at previous review/update) C x L	Current risk score C x L
PR1	Significant deterioration in standards of safety and care	Medical Director	01/04/2018	13/09/2021	4 x 2 = 8	4 x 4 = 16	4 x 4 = 16
PR2	Demand that overwhelms capacity	Chief Operating Officer	01/04/2018	13/09/2021	4 x 2 = 8	4 x 4 = 16	4 x 4 = 16
PR3	Critical shortage of workforce capacity and capability	Director of People	01/04/2018	19/10/2021	4 x 2 = 8	4 x 4 = 16	4 x 4 = 16
PR4	Failure to achieve the Trust's financial strategy	Chief Financial Officer	01/04/2018	26/10/2021	4 x 2 = 8	5 x 3 = 15	4 x 3 = 12
PR5	Inability to initiate and implement evidenced based improvement and innovation	Director of Culture & Improvement	17/03/2020	19/10/2021	3 x 2 = 6	3 x 3 = 9	3 x 3 = 9
PR6	Working more closely with local health and care partners does not fully deliver the required benefits	Chief Executive Officer	01/04/2020	12/10/2021	2 x 2 = 4	2 x 3 = 6	2 x 3 = 6
PR7	Major disruptive incident	Director of Corporate Affairs	01/04/2018	12/10/2021	4 x 1 = 4	4 x 2 = 8	4 x 2 = 8



Principal risk (what could prevent us achieving this strategic objective)	Significant deterioration	R 1: Significant deterioration in standards of safety and care gnificant deterioration in standards of safety and quality of patient care across the Trust resulting in substantial incidents of voidable harm and poor clinical outcomes							1. To provide outstanding care	
Lead Committee	Quality	Risk rating	Current exposure	Tolerable	Risk type	Patient harm	25			
Executive lead	Medical Director	Consequence	4. High	4. High	4. High	Risk appetite	Minimal	15	Current risk lev	rel
Initial date of assessment	01/04/2018	Likelihood	4. Somewhat likely	3. Possible	2. Unlikely			10 5	Tolerable risk	
Last reviewed	13/09/2021	Risk rating	16. Significant	12. High	8. Medium			0 - 20 - 20 - 20 - 20 - 20 - 20 - 20 -	level	el l
Last changed	13/09/2021							Oct- Nov-; Dec-	Mar-21 May-21 Jun-21 Jul-21 Sep-21 Sep-31	

	2021					0 2 0 5 4	2	
Strategic threat (what might cause this to happen)		ontrols ms & processes do we already have in place to the risk and reducing the likelihood/impact of	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we a	re placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
A widespread loss of organisational focus on patient safety and quality of care leading to increased incidence of avoidable harm, exposure to 'Never Events', higher than expected mortality, and significant reduction in patient satisfaction	governance ar service levels in service levels in Monthly me (PSC) with waregistration. Nursing and Clinical policies supporting do Clinical audit parrangements. Clinical staff restraining, regist. Defined safe in wards & depart wards & depart monitored by. Ward assurant programme. Nursing & Mic. AHP Strategy. Scoping and similar linernal Review. Getting it Right dives, reports.	eting of Patient Safety Committee fork programme aligned to CQC regulations Midwifery and AHP Business meeting as, procedures, guidelines, pathways, cumentation & IT systems programme & monitoring ecruitment, induction, mandatory tration & re-validation medical & nurse staffing levels for all rtments (Nursing safeguards	Intranet currently contains some out of date clinical information that may still be accessible Lack of real time data collection	Intranet documents review SLT Lead: Head of Communications Timescale: September 2021 Information, EMPA, EPR and IT Developments in development or progress SLT Lead: Medical Director Timescale: March 2022	Management: Learning from deaths Restrategic Priority Report to Board; Division Committee bi-annually; Guardian of Sar Quality and Governance Reporting Path → Quality Committee reports include: DPR Report to PSC monthly and Quality East Cancer Screening Services Risk & Compliance: Quality Dashboard Account Report QT	sional risk reports to Risk Ife Working report to Board qrtly hway; Patient Safety Committee IC bi-monthly nthly amme IC to QC eport to QC External National Reports Report (Oct 2020) Ife (Sep 2020) and SOF to PSC Monthly; Quality I & Duty of Candour report to PSC IC; Significant Risk Report to RC ION Report 2020 ISSSESSMENTS and reports of: IC Devices (BSI)	None	Positive



Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
An outbreak of infectious disease (such as pandemic influenza; Coronavirus; norovirus; infections resistant to antibiotics) that forces closure of one or more areas of the hospital	 Infection prevention & control (IPC) programme Policies/ Procedures; Staff training; Environmental cleaning audits PFI arrangements for cleaning services Root Cause Analysis and Root Cause Analysis Group Reports from Public Health England received and acted upon Infection control annual plan developed in line with the Hygiene Code Influenza and Covid vaccination programmes Public communications re: norovirus and infectious diseases Coronavirus identification and management process Infection Prevention and Control Board Assurance Framework Outbreak meeting including external representation, CCG, PHE, Regional IPC CQC IPC Key lines of enquiry engagement sessions 	None	N/A	Management: Divisional reports to IPC Committee (every 6 weeks); IPC Annual Report to QC and Board; Water Safety Group; IPC BAF report to PSC and QC Risk & compliance: IPC Committee report to PSC qtrly; SOF Performance Report to Board monthly; IPC Clinical audits in IPCC report to PSC qtrly Independent assurance: Internal audit plan; CQC Rating Good with Outstanding for Care May '20; PLACE Assessment and Scores Estates Governance bi-monthly; Public Health England attendance at IPC Committee; Influenza vaccination cumulative number of staff vaccinated; HSE visit Dec '20 – no concerns highlighted IPC BAF Peer Review by Medway Trust HSE External assessment and report HSIB IPC assessment and report	Learning from the impact on activity, patient safety and staffing due to COVID-19 wave 1 Constraints of critical care capacity and PPE availability dependent on the size of future waves and restoration activity — Business Case approved in principle — no commencement date yet identified Business case to enhance oxygen capacity/flow has been delivered — awaiting further instruction from NHSE/I BOC commencement date Jan 2022 Unable to provide assurance that infection risk is monitored at the front door and documented in the patient notes Information capture to be moved onto the electronic patient record SLT Lead: Chief Nurse Timescale: March 2022	Inconclusive



Principal risk (what could prevent us achieving this strategic objective)	PR 2: Demand that overwhelms capacity Demand for services that overwhelms capacity resulting in a deterioration in the quality, safety and effectiveness of patient care							Stra	tegic objective	1. To provide outstanding ca	e
Lead Committee	Quality	Risk rating	Current exposure	Tolerable	Target	Risk type	Patient harm	25			
Executive lead	Chief Operating Officer	Consequence	4. High	4. High	4. High	Risk appetite	Minimal	20 15			——Current risk level
Initial date of assessment	01/04/2018	Likelihood	4. Somewhat likely	4. Somewhat likely	2. Unlikely			10	•••••		Tolerable risk level
Last reviewed	13/09/2021	Risk rating	16. Significant	16. Significant	8. Medium			0	20 20 21 21	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	······ Target risk level
Last changed	13/09/2021								Oct- Nov- Dec- Jan-	Feb-21 May-21 Jun-21 Jun-21 Aug-21 Sep-21	

Last changed 13/09/2	2021						0 2	Z A T E 4 5		
Strategic threat (what might cause this to happen)	Primary risk conti (what controls/ systems & the risk and reducing the li	processes do we alread	y have in place to assist us in threat)	managing (Specific a where fur required t	n control areas / issues ther work is to manage the cepted appetite/ level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and d (Evidence that the controls/ system reliance on are effective)		Gaps in assurance / actions to address gap and issues relating to COVID-19 (Insufficient evidence as to effectiveness of the controls or negative assurance)	Assurance rating
Threat: Growth in demand for care caused by an ageing population (forecast annual increase in emergency demand of 4-5% per annum); reduced social care funding and increased acuity leading to more admissions and longer length of stay, or a reduction in capacity to meet current and future demand due to the impact of COVID-19	 Single streaming p with NEMs Trust and System of Cancer Improvement Trust leadership of Patient pathway, so Inter-professional times such as diagonal proactive system of Together Alliance Patient Flow Progrous SFH internal Winter Referral management MSK pathways COVID-19 Incident Some cancer servional Risk assessments to Elective Steering Generational Elective Accelerator Programational Elective Accelerator Programatical Elective Accelerator Programatica	escalation process ent plan f and attendance at some of which are j standards across the nostics are complete eadership engagem Delivery Board amme er capacity plan & Nent systems shared a planning and gove ces maintained dur to prioritise individuation pow meeting mes amme – SFH has be	point with NUH the Trust to ensure turnal the Trust to ensure turnal the description of the tensure turnal the description of the tensure tensure the re- tensure process in COVID-19 the patients in the tensure the re- tensure successful in being pointer attracting £2.5m of	the dem manage scheme system Lack of achieve Mid-Nor for MSF 22 – this associat care part secondary ecovery of art of the	consistent ment of the tts threshold T patients of s is mainly ted with social ckages	There is a plan to implement discharge to assess in October, but without workforce being in place this seems unlikely. This will be picked up via H2 capacity plan for SFH to see what action SFH will need to take	Management: Performance arrangements between Divis Executive Team; Winter Plan to Exec meetings; Cancer 62 to Board; Planning documen clear demand and capacity g and capturing Potential Harn 19 Pandemic report to Board Recovery Plan to Board Sep 'Report to Recovery Committe Steering Group report to Exer Risk & compliance: Divisional Committee bi-annually; Signif monthly; Single Oversight From Monthly Performance Report Control Team governance structures are services report to Board Independent assurance: NH: Team review of cancer process.	sions, Service Lines and a to Board Oct '20; Exec day improvement plan ats for 19/20 to identify aps/bridges; Identifying an Resultant from COVID-d Jun '20; COVID-19 '20; Elective Services tee monthly; Elective ecutive Team weekly al risk reports to Risk ificant Risk Report to RC amework Integrated at to Board; Incident ructure to TMT Mar '20; ard Jun '21 SI Intensive Support		Positive
Threat & Opportunity: Operational failure of General Practice to cope with demand resulting in even higher demand for secondary care as the 'provider of last resort'	failure of General I	Practice egrated Care Syste Care Provider devel meeting with the C	= -				Management: Routine med CCG and SFH risk registers – to risks for primary care staff Independent assurance: 'Dri discussed at Board Aug '19	particularly with regard fing and demand		Inconclusive
Threat & Opportunity: Drop in operational performance of neighbouring providers that creates a shift in the flow of patients and referrals to SFH	role in Integrated (Horizon scanning v relevant Executive	Care Provider devel with neighbour orga Directors ent meeting with th	nisations via meetings e Service Director from	between			Risk and compliance: Divisio partnership forum minutes a service support to SFH paper	and action log; NUH	Lack of control over the flow of patients from the surrounding area	Inconclusive



Principal risk (what could prevent us achieving this strategic objective)	PR 3: Critical shortage of value A shortage of workforce capacity have an adverse impact on patien	and capability re	•	-being which can		Strategic objective	3: To maximise the poter	ntial of our workforce		
Lead Committee	People, Culture & Improvement	Risk rating	Current exposure	Tolerable	Target	Risk type	Services	25 20		
Executive lead	Director of People	Consequence	4. High	4. High	4. High	Risk appetite	Cautious	15		—— Current risk level
Initial date of assessment	01/04/2018	Likelihood	4. Somewhat likely	4. Somewhat likely	2. Unlikely			10 5		Tolerable risk level
Last reviewed	19/10/2021	Risk rating	16. Significant	16. Significant	8. Medium			0 20 20 72 72 72 72 72 72 72 72 72 72 72 72 72	22 22 23 23 22 23 23 24 24 25 25 25 25 25 25 25 25 25 25 25 25 25	······ Target risk level
Last changed	19/10/2021							Nov. Dec. Jan. Feb.	Apr-21 Jun-21 Jul-21 Aug-21 Sep-21	

Last changed 1	19/10/2021							ž č ž ž ž ž ž		
Strategic threat (what might cause this to ha	appen)			ready have in place to assist us in / impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assura (Evidence that the cor reliance on are effective	ntrols/ systems which we are placing	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Threat: Inability to attr staff due to demograph (including a significant external factors and/or circumstances) and shi attitudes to careers, co employment market fa reduced availability and competition), or menta relating to the working resulting in critical wor some clinical services	chic changes impact of or unforeseen ifting cultural combined with actors (such as ad increased cal health issues g environment, rkforce gaps in	 People and Ind Culture and Ind Medical and N Activity, Work 2 year workford Group and rew workforce mo Vacancy mana processes TRAC system for procedures us Defined safe indepartments in departments in departments in departments in departments in departments in defined author Education par Director of Person Workforce pla Communication pensions and pensions restrictly re	nprovement Cabine lursing task force force and Financial ree plan supported riew processes (condelling; winter capagement and recruit or recruitment; e-Red to plan staff util nedical & nurse staff of Safe Staffing Standiffing approval and risation levels therships opple attendance at nning for system wons issued regarding provision of pension ucturing payment ints for at-risk staff paymeded Health and	plan by Workforce Planning sultant job planning; city plans) ment systems and ostering systems and sation fing levels for all wards and lard Operating Procedure recruitment processes with People and Culture Board ork stream g HMRC taxation rules on his advice introduced groups I Wellbeing support system	Lack of Divisional ownership and understanding of their workforce issues	Deliver the People, Culture and Improvement Strategy (People and Inclusion) SLT Lead: Executive Director of People Timescale: March 2022	2018/20; Quarter Board; AHP Strate Midwifery and AH Nov 20to PCI Com ICS/ICP update quereports on People Improvement to F Committee; People COVID-19 Update Retention report I Plan to Board Oct Risk and compliantisk report Month report Risk Comm (Monthly); Bank a Guardian of safe value of resources of Retention report EU Exit Risk System Nottinghamshire Strate Checks internal au assurance; HSJ Aw 2021	nce: Risk Committee significant ly; HR & Workforce planning sittee; SOF – Workforce Indicators and agency report (monthly); working report to Board Nov '20 prance: Well-led report CQC; NHSI report; IA Recruitment & Jan '19 – Significant Assurance; m Overview – Nottingham and System Dec '20; Pre-employment audit report Feb '21 – significant ward for Acute Trust of the Year	Staff becoming infected, leading to increased sickness absence Staff working in unfamiliar roles Staff mental health issues as a result of psychological trauma	Inconclusi
Threat: A significant losproductivity arising fro reduction in staff availareduction in effort abortontractual requirements substantial proportion workforce and/or loss of colleagues from the second by other factors job satisfaction, lack of for personal developments pay restraint, workforce wellbeing issues, or fail	om a short-term lability or a lability or a lability or a labore and beyond ents amongst a labore for experienced ervice, or labore so such as poor fopportunities ment, on-going ce fatigue or	 People and Inc Culture and Inc Chief Executiv Engagement et WAND, Time to Schwartz round Learning from Staff morale ic registers Star of the modeling provisional actions 	vents with Staff Ne o Change) ds COVID dentified as 'profile nth/ milestone eve on plans from staff	t munication bulletin tworks (BAME, LGBT, risk' in Divisional risk	Inequalities in staff inclusivity and wellbeing across protected characteristics groups	Deliver the People, Culture and Improvement Strategy (Culture and Improvement) SLT Lead: Executive Director of People Timescale: March 2022 Deliver the Equality, Diversity and Inclusivity Strategy SLT Lead: Executive Director of People Timescale: March 2022	report to Board O Annual report Jun Board Jun '2021; (addressing; D&I, \ Oct 20 Board; Qua People & Inclusion People Culture an People Culture an Update May '20; I to Board Aug '20; post exercise repo	aff survey, action plan and annual act '20; Diversity & Inclusion '20; WRES and WDES report to Combined assurance report Violence & Aggression, Restraints arterly Assurance reports on and Culture & Improvement to d Improvement Committee; ad Improvement: COVID-19 Equality & Diversity presentation Business Continuity exercises — orts through Resilience Assurance g program); Winter Wellness	Reduction in available staff due to COVID-19, e.g. staff isolating, shielding of vulnerable staff groups and social distancing; redeployment to the vaccination programme Reduction in effort above and beyond contractual requirements due to COVID-19 service restrictions Reluctance of some staff	Inconclusi



Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (Specific areas / issues where further work is required to manage the risk to accepted appetite/ tolerance level)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
consistent values and behaviours in line with desired culture This could also lead to lack of engagement with patients, resulting in failure to address patient empowerment and self-help and failure to work across the system to empower patients and carers to enable personalised patient centred care	 and relationships at work policy) Just and restorative culture Influenza vaccination programme COVID-19 vaccination programme Staff wellbeing drop-in sessions Staff counselling / Occ Health support Enhanced equality, diversity and inclusion focus on workforce demographics Freedom to Speak Up Guardian and champion networks Emergency Planning, Resilience & Response (EPRR) arrangements for temporary loss of essential staffing (including industrial action and extreme weather event) Combined violence and aggression campaign across system partners Anti-racism Strategy 			Campaign report to Board Oct '21 Risk and compliance: EPRR Report (bi-annually); Freedom to speak up self-review Board Oct '20; Freedom to Speak Up Guardian report quarterly; Guardian of Safe Working report to Board Dec '20; Gender Pay Gap report to Board Mar '20; TRAC Performance Report to P, OD&C quarterly; Interim NHS People Plan self-assessment to People Culture & Inclusion Sep '20; Significant Risk Report to RC monthly; Gender Pay Gap report to Board Apr '21 Independent assurance: National Staff Survey Mar '21; SFFT/Pulse surveys (Quarterly); Well-led report CQC	members to return to work due to COVID-19-associated health concerns Restrictions to deployment of key staff due to reduced availability of Mandatory and Statutory Training, and the consequential expiry of certification Increase in violence and aggression towards staff Implement the recommendations from the SWE Expert Group report 'Violence & Aggression and Associated Risks' SLT Lead: Chief Nurse Timescale: March 2022	



Principal risk (what could prevent us achieving this strategic objective)		4: Failure to achieve the Trust's financial strategy ure to achieve agreed trajectories resulting in regulatory action							gic objective	5: To achieve better value	e
Lead Committee	Finance	Risk rating	Current exposure	Tolerable	Target	Risk type	Regulatory action	20 _			
Executive lead	Chief Financial Officer	Consequence	5. Very high 4. High	4. High	4. High	Risk appetite	Cautious	15 +			—— Current risk level
Initial date of assessment	01/04/2018	Likelihood	3. Possible	3. Possible	2. Unlikely			10 + 5 +	• • • • • • • • • • • • • • • • • • • •		Tolerable risk level
Last reviewed	26/10/2021	Risk rating	15. Significant 12. High	12. High	8. Medium			0 +	, , , , , , , , , , , , , , , , , , ,		······ Target risk level
Last changed	26/10/2021								Nov-2 Dec-3 Jan-2 Feb-2	Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21	

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps	Assurance rating
Threat: A reduction in funding or change in financial trajectory or unexpected event resulting in an increased Financial Improvement Plan (FIP) requirement to reduce the scale of the financial deficit, without having an adverse impact on quality and safety	 5 year long term financial model Working capital support through agreed loan arrangements Annual plan, including control total consideration; reduction of underlying financial deficit and unwinding of the PFI benefit by £0.5m annually Engagement with the Better Together alliance programme Transformation and Efficiency Cabinet, FIP planning processes and PMO coordination of delivery Delivery of budget holder training workshops and enhancements to financial reporting A full 'wash up' of portfolio planning, delivery and engagement conducted; recovery plan in place, Board approved & governance in place Medical Pay Task Force action plan in place Close working with ICS partners to identify system-wide planning, transformation and cost reductions Executive oversight of commitments All costs and required cash associated with COVID 19 funded in full for period 1/4/20 to 30/9/20 COVID-19 related funding application process in place at Trust level 2021/22 Planning guidance confirms continuation of 20/21 funding regime for H1 and H2 	No long term commitment received for liquidity / cash support Lack of identification of opportunities for recurrent delivery of FIP Lack of clarity on the financial regime for 21/22 H2	Full receipt of required cash following delivery of NHSI required future trajectories SLT Lead: Chief Financial Officer Timescale: 2021/22 H2 plan submission date (TBC by NHSI)end November 2021 Full review of ability to improve recurrent delivery of FIP within financial planning for 2021/22 SLT Lead: Director of Culture and Improvement Timescale: 2021/22 H2 plan submission date (TBC by NHSI)end November 2021 H1 and H2 budget setting process for 2021/22 to include enhanced confirm and challenge SLT Lead: Chief Financial Officer Timescale: 2021/22 H2 plan submission date (TBC by NHSI)end November 2021	Management: Delivery of improved 20/21 financial position; CFO's Financial Reports & FIP Summary (Monthly); Quarterly Strategic Priority Report to Board; Alliance Progress Report & STP FIP (at each Finance Committee meeting); Investment governance work programme; Divisional risk reports to Risk Committee bi-annually Risk and compliance: Risk Committee significant risk report Monthly; Independent assurance: Internal Audit of FIP/ QIPP processes Jul '21; EY Financial Recovery Plan; all costs associated with COVID-19 reimbursed in full to 30/9/20	Awaiting H2 2021/22 NHSI/E planning guidance	Inconclusive
Threat: ICS system deficit results in a negative financial impact to the Trust	 Full participation in ICS planning SFH plan consistency with ICS plan ICS DoFs Group ICS Strategy and Delivery Group 	ICS underlying financial deficit	Full participation in the development of the ICS Financial Strategy and aligned payment mechanisms SLT Lead: Chief Financial Officer Timescale: 2021/22 H2 plan submission date (TBC by NHSI)end November 2021	Risk and compliance: ICS financial reports to Finance Committee; ICS Board updates to SFH Trust Board	Awaiting H2 2021/22 NHSI/E planning guidance	Inconclusive



Principal risk (what could prevent us achieving this strategic objective)	PR 5: Inability to initiate and implement evidence-based improvement and innovation Lack of support, capability and agility to optimise strategic and operational opportunities to improve patient care							Strategic ob	bjective	4: To continuously learn and	improve
Lead Committee	People, Culture & Improvement	Risk rating	Current exposure	Tolerable	Target	Risk type	Patient Harm	10			
Executive lead	Director of Culture & Improvement	Consequence	3. Moderate	3. Moderate	3. Moderate	Risk appetite	Cautious	6			——— Current risk level
Initial date of assessment	17/03/2020	Likelihood	3. Possible	3. Possible	2. Unlikely			4			Tolerable risk level
Last reviewed	19/10/2021	Risk rating	9. Medium	9. Medium	6. Low			0 0 0	3 5 5 5		······ Target risk level
Last changed	19/10/2021							Nov-2 Dec-2	Jan-2 Feb-2 Mar.	Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21	

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Threat: Lack of understanding and agility resulting in reduced efficiency and effectiveness around how we provide care for patients	 Digital Strategy Improvement Strategy People, Culture & Improvement Committee Leadership development programmes Talent management map Programme Management Office Culture & Improvement Cabinet Transformation Cabinet Ideas generator platform 	The full scope of potential issues is not currently known — therefore further investigation is under way	Establishment of an Innovation Hub SLT Lead: Director of Culture and Improvement Timescale: October 2021 January 2022 Recruit a Chief Information Officer SLT Lead: Medical Director Timescale: January 2022 Review of current Digital Strategy objectives and implementation SLT Lead: Medical Director Timescale: December 2021 Recommendations implemented following the review of the EPMA programme of work SLT Lead: Medical Director Timescale: November 2021 Chief Nurse Information Officer (CNIO) Role to be temporarily extended to ensure robust oversight of EPR Development SLT Lead: Medical Director Timescale: November 2021	Management: Monthly Transformation and Efficiency report to FC; Clinical Audit & Improvement report to PSC quarterly; Culture & Improvement Assurance Report to PC&IC bimonthly Risk and compliance: SOF Culture and Improvement indicators; SFH breakthrough objectives to Board quarterly Independent assurance: none currently in place	Delays in training, planned improvement and innovation programmes due to COVID-19 Lack of independent assurance, evidence and insight Development of a Continuous Improvement Maturity Assessment in conjunction with EMAHSN SLT Lead: Director of Culture and Improvement Timescale: December 2021	Positive



Principal risk (what could prevent us achieving this strategic objective)	PR 6: Working more closely with local health and care partners does not fully deliver the required benefits Influencing the wider determinants of health and improving our collective financial position requires close partnership working. This may be difficult because of differences in governance, objectives and appetite for and ability to change.							Strategic objective 2: To promote and support health and wellbeing			ealth and wellbeing
Lead Committee	Risk	Risk rating	Current exposure	Tolerable	Target	Risk type	Services	10 _			
Executive lead	Chief Executive Officer	Consequence	2. Low	2. Low	2. Low	Risk appetite	Cautious	6			—— Current risk level
Initial date of assessment	01/04/2020	Likelihood	3. Possible	4. Possible	2. Unlikely			4 -	•••••		Tolerable risk level
Last reviewed	12/10/2021	Risk rating	6. Low	8. Medium	4. Low			0	22 22 22 27	7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	····· Target risk level
Last changed	12/10/2021								Nov: Dec-: Jan-: Feb-:	Mar-21 Apr-21 Jun-21 Jul-21 Aug-21 Sep-21	

Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Threat: Conflicting priorities, financial pressures (system financial plan misalignment) and/or ineffective governance resulting in a breakdown of relationships amongst ICS and ICP partners and an inability to influence further integration of services across acute, mental, primary and social care	 Mid-Nottinghamshire Integrated Care Partnership Board Mid-Nottinghamshire ICP Executive formed May 2020 Mid-Nottinghamshire ICP breakthrough objectives signed off July 2020 Nottingham and Nottinghamshire Integrated Care System Board Continued engagement with ICP and ICS planning and governance arrangements Quarterly ICS performance review with NHSI Joint development of plans at ICS level Finance Directors Group ICS Planning Group Alignment of Trust, ICS and ICP plans Independent chair for ICP ICS Transition and Risk Committee Approved implementation plan for establishing system risk arrangements ICS Provider Collaborative development 	Continued misalignment in organisational priorities	Delivery of the agreed system priorities SLT Lead: Chief Executive Officer Timescale: March 2022	Management: Alliance Development Summary to Board; Strategic Partnerships Update to Board; mid- Nottinghamshire ICP delivery report to FC (as meeting schedule); Finance Committee report to Board; Nottingham and Nottinghamshire ICS Leadership Board Summary Briefing to Board; Planning Update to Board Risk & compliance: Significant Risk Report to RC monthly Independent assurance: 360 Assurance review of SFH readiness to play a full part in the ICS – Significant Assurance	Delay in delivering the benefits of system working due to the impact of COVID-19	Positive
Threat and Opportunity: Clinical service strategies and/or commissioning intentions that do not sufficiently anticipate evolving healthcare needs of the local population and/or reduce health inequalities	 Continued engagement with commissioners and ICS developments in clinical service strategies focused on prevention Partnership working at a more local level, including active participation in the mid-Nottinghamshire ICP Clinical Services Strategy - 10 of 20 services complete 	Insufficient granularity of plans to meet the needs of the population and the statutory obligations of each individual organisation	Development of a co-produced clinical services strategy for the ICS footprint – 3 rd set of 5 services SLT Lead: Medical Director Timescale: end September 2021	Management: Alliance Development Summary to Board; Strategic Partnerships Update to Board; mid-Nottinghamshire ICP delivery report to FC (as meeting schedule); Finance Committee report to Board; Planning Update to Board Independent assurance: none currently in place	Delay in delivering the benefits of system working due to the impact of COVID-19	Positive



Principal risk (what could prevent us achieving this strategic objective)	PR 7: Major disruptive incident A major incident resulting in temporary hospital closure or a prolonged disruption to the continuity of core services across the Trust, which also impacts significantly on the local health service community							Strategic objective	1: To provide outstanding care	3
Lead Committee	Risk	Risk rating	Current exposure	Tolerable	Target	Risk type	Services	15		
Executive lead	Director of Corporate Affairs	Consequence	4. High	4. High	4. High	Risk appetite	Cautious	10		—— Current risk level
Initial date of assessment	01/04/2018	Likelihood	2. Unlikely	3. Possible	1. Very unlikely			5		Tolerable risk level Target risk level
Last reviewed	12/10/2021	Risk rating	8. Medium	12. High	4. Low			20 -20 -21 -21 -21	21 -21 -21 -21 -21 -21 -21	raiget isk level
Last changed	12/10/2021							Nov. Dec. Jan.	Mar-21 Apr-21 Jun-21 Jul-21 Aug-21 Sep-21	

Last reviewed	12/10/2021	Risk rating	8. Medium	12. High	4. Low			sc-20 ln-21 lb-21	Apr-21 May-21 Jun-21 Jul-21 Aug-21 Sep-21 Oct-21	
Last changed	12/10/2021							N Q L A	i k M M L L A S O	
Strategic threat (what might cause this to	happen) Primary risk controls (what controls/ systems & prod managing the risk and reducing	cesses do we already have in		Gaps in contro (are further controls p in order to reduce risk exposure within tolera range?)	ossible control	trols possible in risk exposure	Sources of assurance (and (Evidence that the controls/ system reliance on are effective)		Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assuran rating
Threat: Shut down IT network due to a scale cyber-attack o system failure that slimits the availability essential informatio prolonged period	NHIS Cyber Security S Cyber Security Progra everely of n for a Network accounts ch disabled after 80 day Major incident plan in Periodic phishing exe	Strategy amme Board & Cyber S ted to all NHIS partners ecked after 50 days of s if not used	Security Project s inactivity – 60 Assurance	Misalignment with NCSC Cyber Secur Metrics: - High Severity Alecompletion and reporting not with required timefram - Unsupported system - Low degree of alignment with NC backup guidance Password criteria not meet IT Healthcheck stand	h Develop and action plant to compliance weeks Cyber Security requirement SLT Lead: Direct Direct Direct Development Developm	deliver an open sure with the NCSC ty Metrics sector of NHIS ecember ckup system in place ing for HSAs orted systems remanagers to o users the of strong ecember sector of NHIS ecember strong ecember of NHIS	Management: Data Protect submission to Board Apr '2 Hygiene Report to Cyber Se NHIS report to Risk Comminanual Report to Risk Com	1- 100% compliance; ecurity Board monthly; ttee quarterly; IG Bimittee; Cyber Security and May '20 60 Assurance Cyber of Jan '19 – Significant mation Security TIAN / 360 Assurance impact of Covid-19 on a Security Report Mar 360 Assurance NHIS audit – limited Data Security and any '21 – substantial sachieved Sep '21; IT	Implement the actions from the NHIS Governance and Interface internal audit report SLT Lead: Medical Director Timescale: March 2022 Cyber Security Essentials Plus mandatory requirement will not be met by June 2021 Address Cyber Security Essentials Plus failures to obtain certification SLT Lead: Director of NHIS Timescale: July 2021	Positiv
Threat: A critical infrastructure failure caused by an interructo the supply of one more utilities (electing gas, water), an uncontrolled fire or security incident or of the built environmentat renders a signiful proportion of the estinaccessible or unserviceable, disruservices for a prolor period	ption or PFI Contract and Estate Partners Fire Safety Strategy NHS Supply Chain res Emergency Prepared arrangements at region arrangements at region incident (e.g. industrict disease; power failure CBRNe) Total PFI Contract and Estate Partners Operational Strategie incident (e.g. industrict disease; power failure CBRNe) Total PFI Contract and Estate Partners Emergency Prepared arrangements at region incident (e.g. industrict disease; power failure CBRNe) Total PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estate Partners Fire Safety Strategy In PFI Contract and Estategy Fire Safety Strategy In PFI Contract and Estategy Fire Safety Strategy Fire Sa	silience planning ness, Resilience & Responal, Trust, division and ses & plans for specific tyial action; fuel shortage e; severe winter weath command structure for Emergency Planning & Committee (RAC) over sing Engineer (Water)	d service levels ypes of major e; pandemic ner; evacuation; major incidents security policies				Management: Central Notice plc monthly performance in Annual Report; Water Safe Committee Jul '20; Patient to QC March '21; Hard and reports Risk & compliance: Month to Risk Committee Independent assurance: Planded to RC Dec '18; EPRR standards compliance ration Assurance; Water Safety re Liaison Committee Oct '19; independent audit; MEMD Recertification Mar '21	eport; Fire Safety ty Update Report to Risk Safety Concerns report soft FM assurance ly Significant Risk Report remises Assurance Report; EPRR Core lig (Oct '19) – Substantial eport (WSP) to Joint le WSP report – hard FM	360 Assurance internal audit of contract management SLT Lead: Associate Director of Estates & Facilities Timescale: September 2021 January 2022	Positiv



Strategic threat (what might cause this to happen)	Primary risk controls (what controls/ systems & processes do we already have in place to assist us in managing the risk and reducing the likelihood/ impact of the threat)	Gaps in control (are further controls possible in order to reduce risk exposure within tolerable range?)	Plans to improve control (are further controls possible in order to reduce risk exposure within tolerable range?)	Sources of assurance (and date) (Evidence that the controls/ systems which we are placing reliance on are effective)	Gaps in assurance / actions to address gaps and issues relating to COVID-19	Assurance rating
Threat: A critical supply chain failure that severely restricts the availability of essential goods, medicines or services for a prolonged period	 NHS Supply Chain resilience planning Business Continuity Management System & Core standards CAS alert system – Disruption in supply alerts Major incident plan in place PPE Strategy PPE Winter Forecast 2020/21 EU Exit Preparation Meetings COVID-19 Pandemic Surge Plan Procurement Influenza Pandemic Business Continuity Plan Interim provision for transmission of personal data to the United Kingdom clause within the EU Exit agreement 	None	N/A	Management: Procurement Annual Report to Audit & Assurance Committee; Oxygen Supply Assurance report to Incident Control Team Apr '20; COVID-19 Governance Assurance Report to Board May '20 Independent assurance: Internal Audit Business Continuity and Emergency Planning Sep '18 – Significant Assurance; 2019/20 Counter Fraud, Bribery and Corruption Annual Report; EU Exit Risk System Overview – Nottingham and Nottinghamshire System Dec '20; 360 Assurance Procurement Review Apr '21 – Significant Assurance		Positive